Chairman’s Letter
Notes
Bayer Links
Investor Relations
Financial Statements
6. Scope of consolidation
 6.1 Changes in the scope of consolidation |
| 6.2 Business combinations and other acquisitions |
| 6.3 Divestitures and discontinued operations |
The consolidated financial statements include all subsidiaries, joint ventures and associates. Subsidiaries are those companies in which Bayer AG directly or indirectly has a majority of the voting rights or from which it is able to derive the greater part of the economic benefit and bears the greater part of the risk by virtue of its power to govern corporate financial and operating policies, generally through an ownership interest of more than 50 percent. Inclusion of such companies’ accounts in the consolidated financial statements begins when Bayer AG starts to exercise control over the company and ceases when it is no longer able to do so.
Joint ventures are companies over which the Bayer Group exercises joint control with a third party. Voting rights are normally divided equally between the two parties or on the basis of a joint venture agreement.
Associates in which Bayer AG exerts significant influence, generally through an ownership interest between 20 and 50 percent, are accounted for by the equity method.
Subsidiaries that do not have a material impact on the Group’s net worth, financial position or earnings, either individually or in aggregate, are not consolidated.
Joint ventures are companies over which the Bayer Group exercises joint control with a third party. Voting rights are normally divided equally between the two parties or on the basis of a joint venture agreement.
Associates in which Bayer AG exerts significant influence, generally through an ownership interest between 20 and 50 percent, are accounted for by the equity method.
Subsidiaries that do not have a material impact on the Group’s net worth, financial position or earnings, either individually or in aggregate, are not consolidated.
6.1 Changes in the scope of consolidation
| Germany | Other countries | Total | |
| Bayer AG and consolidated companies | |||
| December 31, 2006 | 90 | 342 | 432 |
| Changes in the scope of consolidation | (9) | (19) | (28) |
| Additions | - | 4 | 4 |
| Retirements | (21) | (61) | (82) |
| December 31, 2007 | 60 | 266 | 326 |
| Companies included at equity (associates) | |||
| December 31, 2006 | 1 | 5 | 6 |
| Changes in the scope of consolidation | - | - | - |
| Additions | - | - | - |
| Retirements | (1) | - | (1) |
| December 31, 2007 | - | 5 | 5 |
The decrease in the number of fully consolidated companies in 2007 is primarily due to mergers between Group companies in the course of the integration of the Schering group and to the divestitures of H.C. Starck and Wolff Walsrode.
Five joint ventures – the same number as in the previous year – are included by proportionate consolidation in compliance with IAS 31 (Interests in Joint Ventures).
The effect of joint ventures on the Group balance sheet and income statement is as follows:
Five joint ventures – the same number as in the previous year – are included by proportionate consolidation in compliance with IAS 31 (Interests in Joint Ventures).
The effect of joint ventures on the Group balance sheet and income statement is as follows:
|
|
Excluded from consolidation are 115 subsidiaries and 39 associates that in aggregate are immaterial to the net worth, financial position and earnings of the Bayer Group and are recognized at cost of acquisition less any impairments. These companies account for less than 0.4 percent of Group sales, less than 0.7 percent of stockholders’ equity and less than 0.4 percent of total assets.
A list of Bayer AG’s direct and indirect holdings is published in the electronic version of the German Federal Gazette. It is also available directly from Bayer AG on request.
The principal companies consolidated in the financial statements are listed in the following table:
A list of Bayer AG’s direct and indirect holdings is published in the electronic version of the German Federal Gazette. It is also available directly from Bayer AG on request.
The principal companies consolidated in the financial statements are listed in the following table:
| Company Name and Place of Business | Bayer’s interest |
| % | |
| Germany | |
| Bayer Business Services GmbH, Leverkusen | 100 |
| Bayer CropScience AG, Monheim | 100 |
| Bayer CropScience Deutschland GmbH, Langenfeld | 100 |
| Bayer HealthCare AG, Leverkusen | 100 |
| Bayer MaterialScience AG, Leverkusen | 100 |
| Bayer Schering GmbH, Leverkusen | 100 |
| Bayer Schering Pharma AG, Berlin | 96.3 |
| Bayer Technology Services GmbH, Leverkusen | 100 |
| Bayer Vital GmbH, Leverkusen | 100 |
| Currenta GmbH & Co. OHG (formerly Bayer Industry Services GmbH & Co. OHG), Leverkusen | 60 |
| Other European countries | |
| Bayer Antwerpen Comm.V, Belgium | 100 |
| Bayer Biologicals S.r.l., Italy | 100 |
| Bayer B.V., Netherlands | 100 |
| Bayer Consumer Care AG, Switzerland | 100 |
| Bayer CropScience France S.A.S., France | 100 |
| Bayer CropScience S.A., France | 100 |
| Bayer International S.A., Switzerland | 100 |
| Bayer Santé S.A.S., France | 100 |
| Bayer Polyurethanes B.V., Netherlands | 100 |
| Bayer Public Limited Company, U.K. | 100 |
| Bayer Schering Pharma Oy, Finland | 100 |
| Bayer S.p.A., Italy | 100 |
| Química Farmacéutica Bayer S.L., Spain | 100 |
| North America | |
| Bayer Corporate and Business Services LLC, U.S.A. | 100 |
| Bayer Corporation, U.S.A. | 100 |
| Bayer CropScience Inc., Canada | 100 |
| Bayer CropScience LP, U.S.A. | 100 |
| Bayer HealthCare LLC, U.S.A. | 100 |
| Bayer HealthCare Pharmaceuticals Inc., U.S.A. | 100 |
| Bayer Inc., Canada | 100 |
| Bayer MaterialScience LLC, U.S.A. | 100 |
| Bayer Pharmaceuticals Corporation, U.S.A. | 100 |
| BAYPO Limited Partnership, U.S.A. | 100 |
| Medrad Inc., U.S.A. | 100 |
| Asia/Pacific | |
| Bayer Australia Limited, Australia | 100 |
| Bayer HealthCare Co. Ltd., China | 100 |
| Bayer MaterialScience Limited, Hong Kong | 100 |
| Bayer MaterialScience Trading (Shanghai) Company Limited, China | 100 |
| Bayer Polymers Shanghai Co. Ltd., China | 90 |
| Bayer Thai Company Limited, Thailand | 100 |
| Bayer Yakuhin, Ltd., Japan | 100 |
| Latin America /Africa/Middle East | |
| Bayer (Proprietary) Limited, South Africa | 100 |
| Bayer de México, S.A. de C.V., Mexico | 100 |
| Bayer S.A., Argentina | 100 |
| Bayer S.A., Brazil | 100 |
| Bayer Türk Kimya Sanayi Limited Sirketi, Turkey | 100 |
Also included in the consolidated financial statements are the following associates, which are accounted for by the equity method:
| Company Name and Place of Business | Bayer’s interest |
| % | |
| DIC Bayer Polymer Ltd., Japan | 50 |
| Lyondell Bayer Manufacturing Maasvlakte VOF, Netherlands | 50 |
| Palthough Industries (1998) Ltd., Israel | 25 |
| PO JV, LP, U.S.A. | 44.1 |
| Polygal Plastics Industries Ltd., Israel | 25.8 |
The following domestic subsidiaries availed themselves in 2007 of certain exemptions granted under Sections 264, paragraph 3 and 264 b of the German Commercial Code regarding the preparation, auditing and publication of financial statements:
| Company Name | Place of Business |
| Bayer 04 Immobilien GmbH | Leverkusen |
| Bayer 04 Leverkusen Fußball GmbH | Leverkusen |
| Bayer 04 Marketing GmbH | Leverkusen |
| Bayer 04 Mobilien GmbH | Leverkusen |
| Bayer Beteiligungsverwaltungsgesellschaft mbH | Leverkusen |
| Bayer Bitterfeld GmbH | Bitterfeld |
| Bayer Business Services GmbH | Leverkusen |
| Bayer Chemicals AG | Leverkusen |
| Bayer CropScience AG | Monheim |
| Bayer Direct Services GmbH | Leverkusen |
| Bayer Gastronomie GmbH | Leverkusen |
| Bayer Gesellschaft für Beteiligungen mbH | Leverkusen |
| Bayer HealthCare AG | Leverkusen |
| Bayer Innovation GmbH | Düsseldorf |
| Bayer-Kaufhaus GmbH | Leverkusen |
| Bayer MaterialScience AG | Leverkusen |
| Bayer MaterialScience Customer Services GmbH | Leverkusen |
| Bayer Real Estate GmbH (formerly GeWoGe Gesellschaft für Wohnen und Gebäudemanagement mbH) | Leverkusen |
| Bayer Schering GmbH | Leverkusen |
| Bayer Technology Services GmbH | Leverkusen |
| Bayer Vital GmbH | Leverkusen |
| Bayfin GmbH | Leverkusen |
| BerliServe Professional Services GmbH | Berlin |
| Chemion Logistik GmbH | Leverkusen |
| Currenta GmbH & Co. OHG (formerly Bayer Industry Services GmbH & Co. OHG) | Leverkusen |
| Drugofa GmbH | Cologne |
| Dynevo GmbH | Leverkusen |
| EPUREX Films GmbH & Co. KG | Bomlitz |
| Erste K-W-A Beteiligungsgesellschaft mbH | Leverkusen |
| Euroservices Bayer GmbH | Leverkusen |
| Generics Holding GmbH | Leverkusen |
| GP Grenzach Produktions GmbH | Grenzach |
| ICON Genetics GmbH | Munich |
| Intendis GmbH | Berlin |
| Intendis Dermatologie GmbH | Berlin |
| Jenapharm GmbH & Co. KG | Jena |
| Kosinus Grundstücks-Verwaltungs-Gesellschaft mbH & Gamma OHG | Berlin |
| KVP Pharma+Veterinär-Produkte GmbH | Kiel |
| LYTTRON Technology GmbH | Leverkusen |
| Marotrast GmbH | Jena |
| Menadier Heilmittel GmbH | Hamburg |
| Pharma Verlagsbuchhandlung GmbH | Berlin |
| Schering AG | Berlin |
| Schering GmbH und Co. Produktions KG | Weimar |
| Schering International Holding GmbH | Berlin |
| Schering Kahlbaum GmbH | Berlin |
| Sportrechte Vermarktungs- und Verwertungs-GmbH & Co. OHG | Leverkusen |
| TravelBoard GmbH | Leverkusen |
| Zweite K-W-A Beteiligungsgesellschaft mbH | Leverkusen |
6.2 Business combinations and other acquisitions
Acquisitions are accounted for by the purchase method in accordance with IFRS 3 (Business Combinations), the results of the acquired businesses therefore being included in the consolidated financial statements as from the respective dates of acquisition. The purchase prices of acquisitions of companies domiciled outside the euro zone are translated at the exchange rates in effect at the respective dates of acquisition.
Acquisition costs in 2007 amounted to €482 million. The purchase prices of the acquired companies or businesses were settled in cash. Goodwill arising on these acquisitions totaled €210 million.
In June 2006, the wholly owned subsidiary Bayer Schering GmbH acquired a majority interest in Bayer Schering Pharma AG (at that time known as Schering AG), Berlin, Germany, which was included in full effective June 23, 2006 in the consolidated financial statements of the Bayer Group. As of December 31, 2007, Bayer Schering GmbH held 96.32 percent of the shares in Bayer Schering Pharma AG. The purchase price allocation has been completed and is virtually unchanged compared with December 31, 2006.
On May 31, 2007, Bayer CropScience signed an agreement to acquire the U.S. cotton seed producer Stoneville Pedigreed Seed Company from Monsanto for the preliminary purchase price of US$ 314 million (€232 million) including ancillary acquisition costs. This company was included in full effective June 1, 2007 in the consolidated financial statements of the Bayer Group. The goodwill remaining after the purchase price allocation is mainly attributable to technology and distribution synergies. The acquisition strengthens the position of Bayer’s BioScience business unit in the U.S. cotton seed market.
On July 1, 2007, Bayer MaterialScience completed the acquisition of the Ure-Tech Group of Taiwan, the largest producer of thermoplastic polyurethanes (TPU) in the Asia/Pacific region, for US$ 85 million (€63 million).
Bayer HealthCare completed the announced acquisition of a biologics production facility in Emeryville, California, from Novartis. Bayer HealthCare will continue the production of
Betaferon®/Betaseron® in Emeryville and is taking over the entire manufacturing and process technology and the facility’s employees. Novartis has received about US$ 183 million (€137 million) for the acquisition of the production facility, including the Biologics License Application (BLA), the transfer of the related equipment and inventories, and the leasing of certain buildings.
The effects of these and other, smaller acquisitions on the Group’s assets and liabilities as of the respective acquisition dates are shown in the table. Including acquired cash and cash equivalents, they resulted in the following net cash outflow:
Acquisition costs in 2007 amounted to €482 million. The purchase prices of the acquired companies or businesses were settled in cash. Goodwill arising on these acquisitions totaled €210 million.
In June 2006, the wholly owned subsidiary Bayer Schering GmbH acquired a majority interest in Bayer Schering Pharma AG (at that time known as Schering AG), Berlin, Germany, which was included in full effective June 23, 2006 in the consolidated financial statements of the Bayer Group. As of December 31, 2007, Bayer Schering GmbH held 96.32 percent of the shares in Bayer Schering Pharma AG. The purchase price allocation has been completed and is virtually unchanged compared with December 31, 2006.
On May 31, 2007, Bayer CropScience signed an agreement to acquire the U.S. cotton seed producer Stoneville Pedigreed Seed Company from Monsanto for the preliminary purchase price of US$ 314 million (€232 million) including ancillary acquisition costs. This company was included in full effective June 1, 2007 in the consolidated financial statements of the Bayer Group. The goodwill remaining after the purchase price allocation is mainly attributable to technology and distribution synergies. The acquisition strengthens the position of Bayer’s BioScience business unit in the U.S. cotton seed market.
On July 1, 2007, Bayer MaterialScience completed the acquisition of the Ure-Tech Group of Taiwan, the largest producer of thermoplastic polyurethanes (TPU) in the Asia/Pacific region, for US$ 85 million (€63 million).
Bayer HealthCare completed the announced acquisition of a biologics production facility in Emeryville, California, from Novartis. Bayer HealthCare will continue the production of
Betaferon®/Betaseron® in Emeryville and is taking over the entire manufacturing and process technology and the facility’s employees. Novartis has received about US$ 183 million (€137 million) for the acquisition of the production facility, including the Biologics License Application (BLA), the transfer of the related equipment and inventories, and the leasing of certain buildings. The effects of these and other, smaller acquisitions on the Group’s assets and liabilities as of the respective acquisition dates are shown in the table. Including acquired cash and cash equivalents, they resulted in the following net cash outflow:
| Net carrying amount at the date of first-time consolida- tion | Fair-value adjustment | Net carrying amount after the acquisition | |
| € million | |||
| Acquired assets and assumed liabilities | |||
| Goodwill | 6 | 204 | 210 |
| Other intangible assets | 90 | 89 | 179 |
| Property, plant and equipment | 51 | 18 | 69 |
| Other noncurrent assets | 5 | - | 5 |
| Inventories | 83 | (14) | 69 |
| Other current assets | 32 | (1) | 31 |
| Cash and cash equivalents | 1 | - | 1 |
| Provisions for pensions and other post-employment benefits | - | (4) | (4) |
| Other provisions | - | (17) | (17) |
| Financial liabilities | - | (6) | (6) |
| Other liabilities | (31) | (7) | (38) |
| Deferred taxes | - | (1) | (1) |
| Net assets | 237 | 261 | 498 |
| Minority interests | - | - | (16) |
| Purchase prices | - | - | 482 |
| of which ancillary acquisition costs | - | - | 4 |
| Acquired cash and cash equivalents | - | - | 1 |
| Net cash outflow for the acquisitions | - | - | 481 |
6.3 Divestitures and discontinued operations
Proceeds from divestitures in 2007 amounted to €5,421 million. The principal divestitures were as follows:
Diagnostics business
On June 29, 2006, Bayer AG concluded an agreement with Siemens AG for the latter to acquire the diagnostics business. The Bayer Group sold this business of Bayer HealthCare to Siemens AG, Munich, in January 2007 for €4.3 billion. Transfer of the business to the acquirer was completed on January 2, 2007. An initial payment of €0.4 billion had already been received at the end of 2006.
H.C. Starck
On November 23, 2006, an agreement was concluded to divest the activities of the H.C. Starck Group, formerly assigned to the Materials segment, to a consortium of two financial investors, Advent International and The Carlyle Group, for a purchase price of €1.2 billion less the assumption of some €0.3 billion in financial liabilities and €0.2 billion in pension obligations. Closing of the transaction took place on February 1, 2007.
Wolff Walsrode
An agreement was signed on December 18, 2006 to sell the companies of the Wolff Walsrode Group, which operates principally in the field of cellulose chemistry, to The Dow Chemical Company, U.S.A., for a purchase price of €0.5 billion less the assumption of financial liabilities and pension obligations totaling about €0.1 billion. Wolff Walsrode also was formerly assigned to the Materials segment. Following approval of the transaction by the antitrust authorities, closing took place on June 30, 2007.
The effects of these and other, smaller divestitures on the Group’s assets and liabilities as of the respective divestiture dates were as follows:
Diagnostics business
On June 29, 2006, Bayer AG concluded an agreement with Siemens AG for the latter to acquire the diagnostics business. The Bayer Group sold this business of Bayer HealthCare to Siemens AG, Munich, in January 2007 for €4.3 billion. Transfer of the business to the acquirer was completed on January 2, 2007. An initial payment of €0.4 billion had already been received at the end of 2006.
H.C. Starck
On November 23, 2006, an agreement was concluded to divest the activities of the H.C. Starck Group, formerly assigned to the Materials segment, to a consortium of two financial investors, Advent International and The Carlyle Group, for a purchase price of €1.2 billion less the assumption of some €0.3 billion in financial liabilities and €0.2 billion in pension obligations. Closing of the transaction took place on February 1, 2007.
Wolff Walsrode
An agreement was signed on December 18, 2006 to sell the companies of the Wolff Walsrode Group, which operates principally in the field of cellulose chemistry, to The Dow Chemical Company, U.S.A., for a purchase price of €0.5 billion less the assumption of financial liabilities and pension obligations totaling about €0.1 billion. Wolff Walsrode also was formerly assigned to the Materials segment. Following approval of the transaction by the antitrust authorities, closing took place on June 30, 2007.
The effects of these and other, smaller divestitures on the Group’s assets and liabilities as of the respective divestiture dates were as follows:
| 2007 | |
| € million | |
| Divested assets and liabilities | |
| Goodwill | 36 |
| Other intangible assets | 382 |
| Property, plant and equipment | 884 |
| Other financial assets | 85 |
| Inventories | 800 |
| Other current assets | 1,039 |
| Cash and cash equivalents | 219 |
| Pension and other post-employment benefits | (307) |
| Other provisions | (184) |
| Financial liabilities | (403) |
| Other liabilities | (579) |
| Net assets | 1,972 |
The effects of these and other, smaller divestitures recognized in other operating income and expenses on Group earnings were as follows:
| 2007 | |
| € million | |
| Divestiture proceeds | 5,421 |
| - Net assets | 1,972 |
| - Divestiture costs | 80 |
| - Other adjustments | 213 |
| Net gain from the divestitures (before taxes) | 3,156 |
Discontinued operations
The diagnostics activities, H.C. Starck and Wolff Walsrode are recognized as discontinued operations in 2007. The corresponding information is provided from the standpoint of the Bayer Group and is not intended as a separate presentation of the divested activities.
A breakdown of the results of discontinued operations is given below:
The diagnostics activities, H.C. Starck and Wolff Walsrode are recognized as discontinued operations in 2007. The corresponding information is provided from the standpoint of the Bayer Group and is not intended as a separate presentation of the divested activities.
A breakdown of the results of discontinued operations is given below:
| Diagnostics | H.C. Starck | Wolff Walsrode | Total | |||||
| € million | 2006 | 2007 | 2006 | 2007 | 2006 | 2007 | 2006 | 2007 |
| Net sales | 1,526 | 0 | 985 | 74 | 334 | 172 | 2,845 | 246 |
| Cost of goods sold | (660) | 0 | (806) | (51) | (233) | (109) | (1,699) | (160) |
| Selling expenses | (394) | (1) | (51) | (4) | (45) | (22) | (490) | (27) |
| Research and development expenses | (124) | 0 | (28) | (2) | (8) | (4) | (160) | (6) |
| General administration expenses | (94) | (1) | (32) | (2) | (19) | (9) | (145) | (12) |
| Other operating income (expenses) - net | (51) | 2,821 | (13) | 90 | 11 | 246 | (53) | 3,157 |
| Operating result (EBIT) | 203 | 2,819 | 55 | 105 | 40 | 274 | 298 | 3,198 |
| Non-operating result | (1) | 0 | (5) | (1) | (7) | (3) | (13) | (4) |
| Income before income taxes | 202 | 2,819 | 50 | 104 | 33 | 271 | 285 | 3,194 |
| Income taxes | (85) | (766) | (18) | (5) | (13) | (13) | (116) | (784) |
| Income after taxes | 117 | 2,053 | 32 | 99 | 20 | 258 | 169 | 2,410 |
| of which: | ||||||||
| Current income (loss) (before taxes) | 202 | (16) | 50 | 11 | 33 | 26 | 285 | 21 |
| Income taxes | (85) | 4 | (18) | (3) | (13) | (7) | (116) | (6) |
| Current income (loss) (after taxes) | 117 | (12) | 32 | 8 | 20 | 19 | 169 | 15 |
| Income from the divestitures (before taxes) | - | 2,835 | - | 93 | - | 245 | - | 3,173 |
| Income taxes | - | (770) | - | (2) | - | (6) | - | (778) |
| Income from the divestitures (after taxes) | - | 2,065 | - | 91 | - | 239 | - | 2,395 |
Divestitures of discontinued operations in 2007 resulted in the following cash flows:
| 2007 | |
| € million | |
| Divestiture proceeds | 5,415 |
| Prepayments and outstanding payments | (400) |
| Divestiture costs | (76) |
| Divested cash and financial loans | 186 |
| Tax payments | (443) |
| Other cash flows | (34) |
| Net cash inflow from the divestitures | 4,648 |
The separate asset and liability line items in the balance sheet reflect the following amounts pertaining to the discontinued operations as of December 31:
| Diagnostics | H.C. Starck | Wolff Walsrode | Total | |||||
| € million | 2006 | 2007 | 2006 | 2007 | 2006 | 2007 | 2006 | 2007 |
| Noncurrent assets | 822 | - | 391 | - | 214 | - | 1,427 | - |
| Goodwill and other intangible assets | 383 | - | 33 | - | 8 | - | 424 | - |
| Property, plant and equipment | 356 | - | 300 | - | 194 | - | 850 | - |
| Other noncurrent assets | 42 | - | 15 | - | 2 | - | 59 | - |
| Deferred taxes | 41 | - | 43 | - | 10 | - | 94 | - |
| Current assets | 700 | 76 | 676 | - | 122 | 8 | 1,498 | 84 |
| Inventories | 235 | - | 506 | - | 61 | - | 802 | - |
| Trade accounts receivable | 422 | - | 162 | - | 53 | - | 637 | - |
| Other current assets | 43 | 76 | 8 | - | 8 | 8 | 59 | 84 |
| Assets held for sale and discontinued operations | 1,522 | 76 | 1,067 | - | 336 | 8 | 2,925 | 84 |
| Noncurrent liabilities | 33 | - | 233 | - | 115 | - | 381 | - |
| Provisions for pensions and other post- employment benefits | 26 | - | 182 | - | 89 | - | 297 | - |
| Other provisions | - | - | 30 | - | 7 | - | 37 | - |
| Financial liabilities | - | - | - | - | - | - | - | - |
| Other noncurrent liabilities | - | - | - | - | - | - | - | - |
| Deferred taxes | 7 | - | 21 | - | 19 | - | 47 | - |
| Current liabilities | 299 | 176 | 125 | - | 43 | - | 467 | 176 |
| Other provisions | 100 | 129 | 20 | - | 11 | - | 131 | 129 |
| Financial liabilities | - | - | 58 | - | 8 | - | 66 | - |
| Trade accounts payable | 74 | - | 29 | - | 16 | - | 119 | - |
| Other current liabilities | 125 | 47 | 18 | - | 8 | - | 151 | 47 |
| Liabilities directly related to assets held for sale and discontinued operations | 332 | 176 | 358 | - | 158 | - | 848 | 176 |
Discontinued operations affected the Group cash flow statements as follows:
| Diagnostics | H.C. Starck | Wolff Walsrode | Total | |||||
| € million | 2006 | 2007 | 2006 | 2007 | 2006 | 2007 | 2006 | 2007 |
| Net cash provided by (used in) operating activities | 154 | (34) | 78 | 23 | 43 | 13 | 275 | 2 |
| Net cash provided by (used in) investing activities | (107) | 3,292 | (55) | 927 | (17) | 429 | (179) | 4,648 |
| Net cash provided by (used in) financing activities | (47) | (3,258) | (23) | (950) | (26) | (442) | (96) | (4,650) |
| Change in cash and cash equivalents | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Bookmark this page
E-mail this page
Advanced Search
